At the annual INTERTB meeting on October 22nd 2018 in London PanACEA Coordinator Martin Boeree  and other renown experts on TB clinical drug development came together to discuss the research developments in the field. The 50 mg/kg rifampicin arm in the HR1 trial is completed and Martin Boeree lifted the veil on the preliminary results. We look forward to sharing the results as soon as we can!